viewCircassia Group PLC

Two US approvals spell big business potential for Circassia

Circassia Pharmaceuticals PLC (LON:CIR) is a company focussed on treating patients with respiratory diseases which has just won two new significant US approvals.The approvals could unlock hundreds of millions of dollars of potential market share which could transform the business. Circassia CEO Steve Harris tells Proactive London how the products fit into the rest of the portfolio and why this hurdle is also important for patients suffering from COPD and CHD.
Circassia has several other asthma and COPD treatments in its pipeline including  AirNOvent – a portable system that uses electricity to make nitric oxide in turn to dilate blood vessels in the lungs.

Quick facts: Circassia Group PLC

Price: 27.8 GBX

Market: LSE
Market Cap: £104.8 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Group PLC named herein, including the promotion by the Company of Circassia Group PLC in any Content on the Site, the Company...



Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19

2 min read